[1] |
Palakkan AA, Hay DC, PR AK, et al. Liver tissue engineering and cell sources: issues and challenges[J]. Liver Int, 2013, 33: 666-676.
|
[2] |
Devarbhavi H, Asrani SK, Arab JP, et al. Global burden of liver disease: 2023 update[J]. J Hepatol, 2023, 79: 516-537.
|
[3] |
Si-Tayeb K, Lemaigre FP, Duncan SA. Organogenesis and development of the liver[J]. Dev Cell, 2010, 18: 175-189.
|
[4] |
Matchett KP, Wilson-Kanamori JR, Portman JR, et al. Multimodal decoding of human liver regeneration[J]. Nature,2024,630:158-163.
|
[5] |
Lam DTUH, Dan YY, Chan YS, et al. Emerging liver organoid platforms and technologies[J]. Cell Regen, 2021, 10: 1-19.
|
[6] |
Hu H, Gehart H, Artegiani B, et al. Long-term expansion of functional mouse and human hepatocytes as 3D organoids[J]. Cell, 2018, 175: 1591-1606.
|
[7] |
González F, Zhu Z, Shi ZD, et al. An iCRISPR platform for rapid, multiplexable, and inducible genome editing in human pluripotent stem cells[J]. Cell Stem Cell, 2014, 15: 215-226.
|
[8] |
Nejak-Bowen KN, Monga SPS. Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad[J]. Semin Cancer Biol, 2011, 21: 44-58.
|
[9] |
闫煜聪, 杨淑春, 贾玉艳, 等. 通过定向内胚层的高效分化提高多能干细胞体外生成肝细胞样细胞的效率[J]. 基础医学与临床, 2023, 43: 1045-1052.
|
[10] |
Mun SJ, Ryu JS, Lee MO, et al. Generation of expandable human pluripotent stem cell-derived hepato-cyte-like liver organoids[J]. J Hepatol, 2019, 71: 970-985.
|
[11] |
Macchi F, Sadler KC. Unraveling the epigenetic basis of liver development, regeneration and disease[J]. Trends Genet, 2020, 36: 587-597.
|
[12] |
Monga SPS, Pediaditakis P, Mule K, et al. Changes in WNT/β-catenin pathway during regulated growth in rat liver regeneration[J]. Hepatology, 2001, 33: 1098-1109.
|
[13] |
Wang W, Liu P, Lavrijsen M, et al. Evaluation of AXIN1 and AXIN2 as targets of tankyrase inhibition in hepatocellular carcinoma cell lines[J]. Sci Rep, 2021, 11: 7470. doi: 10.1038/s41598-021-87091-4.
|
[14] |
Han X, Cai C, Deng W, et al. Landscape of human organoids: ideal model in clinics and research[J]. Innovation, 2024, 5: 100620 doi: 10.1016/j.xinn.2024.100620.
|
[15] |
Hendriks D, Brouwers JF, Hamer K, et al. Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis[J]. Nat Biotechnol, 2023, 41: 1567-1581.
|